232 citations
,
January 2002 in “Mechanisms of development” Different enzymes are active in different parts of developing mouse organs.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
3 citations
,
March 1981 in “Journal of Toxicology and Environmental Health” Rats developed lung issues from the drugs, but these cleared quickly after stopping them.
42 citations
,
May 1997 in “The Journal of Biochemistry” PAD type III enzyme is specific to rat skin and hair follicles.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
May 2018 in “The Journal of Immunology” A(1-7) treatment reduces symptoms of lupus in mice.
October 2024 in “Journal of the Endocrine Society” Misdiagnosis led to unnecessary treatment due to a genetic mutation affecting thyroid hormone resistance.
December 2018 in “Bioscience Journal” Leporacarus gibbus mite was found in a domestic rabbit in Espírito Santo, Brazil, for the first time.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
28 citations
,
February 2010 in “Experimental Dermatology” The frizzy mouse and hairless rat mutations are due to changes in the Prss8 gene.
3 citations
,
September 2015 in “Journal of Vascular Surgery” Chemical lumbar sympathectomy is an effective and safe treatment for idiopathic livedo reticularis.
October 2018 in “bioRxiv (Cold Spring Harbor Laboratory)” Neuronatin is found in various cells of rat tissues and has a unique location in sperm cells.
8 citations
,
May 2022 in “International journal of nanomedicine” Lecithin-encapsulated resveratrol nanoparticles could be a safe and effective anti-cancer treatment.
May 2024 in “International journal of medicine and psychology.” Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
A new syndrome, Teelwani Syndrome, combines features of two rare genetic disorders.
7 citations
,
January 1998 in “EXPERIMENTAL ANIMALS” The skin of both rat strains showed similar lectin binding patterns.
36 citations
,
July 2005 in “Journal of Neuroendocrinology” Blocking certain brain processes reduces mating behavior in female rats.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
4 citations
,
August 2022 in “Cells” lncRNA2919 slows down rabbit hair growth by stopping cell growth and causing cell death.
14 citations
,
October 2020 in “Journal of ethnopharmacology” Lepidium sativum seed extracts helped reduce inflammation and improve insulin response in obese rats on a high-fat diet.
1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
January 2025 in “Biomedicines” High testosterone levels can harm fertility by disrupting the LIF signaling pathway in the uterus.
September 2024 in “Journal of the American Academy of Dermatology” The patient responded well to treatment with no disease progression.